StockData

Nuvation Bio vs Verastem

NUVB and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NUVB and VSTM compare

Nuvation Bio is the larger company, worth 1.9 times as much as Verastem ($1.4B against $741M).

Nuvation Bio keeps more of each dollar of sales as profit, with a net margin of −67.4% compared with −178% at Verastem.

Nuvation Bio scores higher on the StockData Score (4 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNUVBVSTM
Size and price
Market cap$1.4B$741M
Share price$3.99$8.18
Change, 1 year−19.1%−3.9%
Change, 5 years−55.9%−77.0%
Beta (5Y)1.451.37
Employees298102
StockData Score
Total score4 (better)3
Valuation score00
Growth score11
Performance score11
Health score2 (better)1
Dividend score00
Valuation
P/S6.9× (better)7.4×
P/B6.1× (better)73.3×
Fair value$1.94–
Margin of safety−105%–
Growth
Revenue growth (TTM)654%–
Revenue growth, 5Y average–−19.0%
Profitability
Operating margin−61.2% (better)−194%
Net margin−67.4% (better)−178%
Return on equity−49.1%–
Financial health
Debt / equity0.03–
Interest coverage−5.9× (better)−141.9×
Current ratio7.45 (better)1.93
Altman Z-score0.06 (better)−7.82
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions66.5%109%
Held by insiders24.6%1.8%
Insider net buying, 12 months−$4.5M−$816K (better)
Superinvestors holding2–
Short interest, % of float23.4%22.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.